Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | Lymphoma: predicting response

Frederick Locke • 2 Jun 2019
ASCO 2019
Lymphoma Axicabtagene ciloleucel

Frederick Locke, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the methods that can be used to predict durable response in lymphoma patients being treated with CAR T-cell therapy. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Frederick Locke

Integrating autoimmune diseases into cellular therapy centers 26:06
Integrating autoimmune diseases into cellular therapy centers
David Miklos et al. • 12 Apr 2025
Real-world trends of CRS and ICANS among patients receiving axi-cel for R/R LBCL: a CIBMTR Report 1:47
Real-world trends of CRS and ICANS among patients receiving axi-cel for R/R LBCL: a CIBMTR Report
Frederick Locke • 7 Dec 2024
Real-world efficacy and safety of tisagenlecleucel in patients with R/R follicular lymphoma 1:05
Real-world efficacy and safety of tisagenlecleucel in patients with R/R follicular lymphoma
Frederick Locke • 7 Dec 2024
Key predictors of success when administering CAR-T for DLBCL 1:35
Key predictors of success when administering CAR-T for DLBCL
Frederick Locke • 7 Dec 2024

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals